AI Launches the Next Biotech Revolution: These Three Shovel Sellers Benefit Regardless of the Next Blockbuster

Personalized cancer therapies have made a decisive step towards commercial medicine. In August, Moderna and Merck achieved an important breakthrough with their individually developed mRNA cancer vaccine Intismeran Autogene in a large Phase 3 study for melanoma. Meanwhile, AI is increasingly making its way into drug development, laboratories, clinical trials, and diagnostics. For investors, an interesting second layer of the investment story emerges: Instead of betting on whether Moderna, BioNTech, or another pharmaceutical company will develop...